FY 2008 (No.246-256)
Japanese
version
issued
on |
No. |
Table of contents |
Posted
on |
PDF |
| March 26, 2009 |
256 |
- Skin necrosis / ulcer following injection of hydroxyzine hydrochloride
- Important Safety Information
(1)Tocilizumab (Genetical recombination)
- List of products subject to Early Post-marketing Phase Vigilance
|
April 20, 2009 |
(Full text) |
| February 26, 2009 |
255 |
- Important Safety Information
(1)Sorafenib Tosilate
(2)Etanercept (genetical recombination)
(3)Temozolomide
(4)Rituximab (genetical recombination)
- Revision of PRECAUTIONS (No. 204)
Aripiprazole (and 13 others)
- List of products subject to Early Post-marketing Phase Vigilance
<Reference>
- Precautions regarding abnormal behaviour when infected with influenza
|
March 13, 2009 |
(Full text) |
| January 29, 2009 |
254 |
- Pharmaceuticals and Medical Devices Information E-mail Alert Service
- Important Safety Information
(1)Enteral nutrition (Elental, Elental P, Ensure-H, Ensure Liquid, Enterued, Twinline, Harmonic-F, Harmonic-M, Racol)
(2)Lornoxicam
- Revision of PRECAUTIONS (No. 203)
Ergotamine Tartrate-Anhydrous Caffeine (and 6 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
February 18, 2009 |
(Full text) |
| December 18, 2008 |
253 |
- Revision of PRECAUTIONS (No. 202)
(1)Amantadine Hydrochloride (and 3 others)
(2)Insulin Pen
- List of products subject to Early Post-marketing Phase Vigilance
|
January 9, 2009 |
(Full text) |
| November 27, 2008 |
252 |
- Hypermagnesaemia following the administration of magnesium oxide
- Important Safety Information
(1)Azelnidipine
- Revision of PRECAUTIONS (No. 201)
(1)Bromocriptin Mesilate (and 13 others)
(2)Ureteral Stent
- List of products subject to Early Post-marketing Phase Vigilance
|
November 27, 2008 |
(Full text) |
| October 30, 2008 |
251 |
- Adverse Drug Reaction Relief System and Relief System for Infections Derived from Biological Products
- Airway clogging of heat and moisture exchangers due to use in combination with heated humidifier
- List of products subject to Early Post-marketing Phase Vigilance
<Reference>
- Reports on adverse reactions associated with influenza vaccines in FY 2007
(Conclusion of the vaccine adverse reaction review committee)
|
November 28, 2008 |
(Full text) |
| September 25, 2008 |
250 |
- Interstitial pneumonia from interferon preparations (preparations with the indication for "improvement of viraemia in chronic hepatitis C")
- Revision of PRECAUTIONS (No. 200)
Gefitinib (and 9 others)
- List of products subject to Early Post-marketing Phase Vigilance
<Reference>
- Results of the Gefitinib domestic phase III study and opinions on Gefitinib use etc.
|
October 21, 2008 |
(Full text) |
| August 28, 2008 |
249 |
- Important Safety Information
(1)Tiotropium Bromide Hydrate
- Revision of PRECAUTIONS (No. 199)
Bucillamine and (5 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
September 12, 2008 |
(Full text) |
| July 23, 2008 |
248 |
- Revision of PRECAUTIONS (No. 198)
(1)Bepridil Hydrochloride (and 1 other)
- List of products subject to Early Post-marketing Phase Vigilance
|
|
(Full text) |
| June 26, 2008 |
247 |
- Revision of PRECAUTIONS (No. 197)
(1)Carbamazepine (and 3 others)
- List of products subject to Early Post-marketing Phase Vigilance
<Reference>
- Information on Heparin Sodium Products etc.
|
|
(Full text) |
| May 22, 2008 |
246 |
- Revision of PRECAUTIONS (No. 196)
(1)Desmopressin Acetate (drug products with the indication for nocturnal enuresis) and 4 others
(2)Coronary drug-eluting stent
- List of products subject to Early Post-marketing Phase Vigilance
<Reference>
- Manuals for Management of Individual Serious Adverse Drug Reactions
- Increasing the number of cooperating hospitals in the project for "Japan Drug Information Institute in Pregnancy"
|
|
(Full text) |
